Saturday, July 25, 2026

pharma · Generalized Pustular Psoriasis · Schizophrenia · VNDA

Vanda Pharmaceuticals Netherlands

Vanda Pharmaceuticals Netherlands clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US HQ
2003 Founded
600 Employees
Public company Type
VNDA · NYSE Ticker
Company details
Status
Public
HQ
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
Founded
2003
Employees
600
Programs
4
Drugs
9
Patents
56
Intelligence · Clinical Programs

Vanda Pharmaceuticals Netherlands projects

1 ClinicalTrials.gov programs sponsored by Vanda Pharmaceuticals Netherlands.

Vanda Pharmaceuticals Netherlands has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. VHX-896 and iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Vanda Pharmaceuticals Netherlands have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.